



이름: 이민철/Min-Cheol Lee, MD, PhD.

직위: 연구개발 부문 사장/CTO and President

소속: (주) 씨젠/Seegene Inc.

기타소속:

**강연제목:** (주)씨젠은 SARS-CoV-2 유전자 진단 제품을 어떻게 만들었을까?

(How did the Seegene Inc. see the genes of SARS-CoV-2?)

### Abstract:

The COVID-19 pandemic has brought two major changes to the public in the laboratory medicine; one is to realize the PCR tests, and the second is to introduce self-testing kits allowing convenient testing process individually. With the belief that three solutions to overcome pandemic are accurate diagnosis, effective quarantine and proper treatment, the Seegene Inc. has launched 15 different PCR assays for molecular diagnosis of COVID-19 infection including detection of new mutants as well as other viruses causing similar respiratory symptoms for differential diagnosis. Development of molecular diagnostic assays is a comprehensive process encompassing broad expertise of medical and biological engineering and IT, which made it possible for us to overcome the pandemic successfully. There are endless efforts mandated to develop a better assay with improved usability for the public and medical personnel requiring the role of biological engineering scientists.

### Brief Biosketch

Lee Min-Cheol, MD, PhD. is currently a Chief Technology Officer and President of Research and Development (R&D), Seegene Inc. He served 36 years as a professor of pathology majoring neuropathology at Chonnam National University Medical School (CNUMS), and 10 years as a research professor of Gwangju Institute of Science and Technology (GIST). His research focused on abnormal development of brain and epilepsy, brain tumors, neural stem cells, and stroke. He served as an advisor of the Minister of Agriculture for prevention of the prion disease, Committee Chair of Neuroscience in the Korea Research Foundation, dean of CNUMS and Graduate School, president of the Korean Society of Pathology, and awarded the "Professor of the Year 2018" by the Korean Association of Medical Colleges (KAMC) for his excellences in medical education, research, service and social contribution. He published 130 research papers in international journals and 21 books. After his retirement at the CNUMS and GIST, he joined the Seegene Inc. as an advisor of R&D on Sep. 2019.